Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Phase 3

Conditions: Advanced Gastric Cancer

Interventions: Drug: Paclitaxel
Drug: capecitabine
Drug: cisplatin

First Posted Date: 2009-11-18

Last Posted Date: 2015-05-19

Lead Sponsor: Peking University

Target Recruit Count: 320

Registration Number: NCT01015339

Locations: 🇨🇳
Department of GI Oncology, Peking University, School of Oncology, Beijing, Beijing, China

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Everolimus

First Posted Date: 2009-11-17

Last Posted Date: 2014-03-26

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01014351

Locations: 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hematology of SW Indiana, Evansville, Indiana, United States

and more 9 locations

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Imatinib mesylate
Drug: Paclitaxel

First Posted Date: 2009-11-11

Last Posted Date: 2015-07-03

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 34

Registration Number: NCT01011075

Locations: 🇺🇸
Univ. of Washington Fred Hutchinson Cancer Research Center (UW-FHCRC), Seattle, Washington, United States
🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Stage IV Breast Cancer
Breast Cancer
Recurrent Breast Cancer

Interventions: Biological: panitumumab
Drug: paclitaxel
Drug: carboplatin
Procedure: laboratory biomarker analysis
Procedure: immunohistochemistry staining method

First Posted Date: 2009-11-09

Last Posted Date: 2018-07-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 14

Registration Number: NCT01009983

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Trastuzumab
Drug: Neratinib
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2009-11-05

Last Posted Date: 2021-10-25

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 141

Registration Number: NCT01008150

Locations: 🇺🇸
Edward Cancer Center Plainfield, Plainfield, Illinois, United States
🇺🇸
University Hospital and Medical Center - SUNY Stony Brook, Stony Brook, New York, United States
🇺🇸
West Virginia University Hospitals Inc., Morgantown, West Virginia, United States

and more 38 locations

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Phase 3

Terminated

Conditions: Melanoma

Interventions: Drug: Tasisulam-sodium
Drug: Paclitaxel

First Posted Date: 2009-11-01

Last Posted Date: 2018-07-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 336

Registration Number: NCT01006252

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Phase 2

Completed

Conditions: Stage IB Uterine Corpus Cancer AJCC v7
Stage II Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage IIIB Uterine Corpus Cancer AJCC v7
Endometrial Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2009-10-30

Last Posted Date: 2018-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01005329

Locations: 🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇺🇸
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 38 locations